Skip to main
OSTX

OSTX Stock Forecast & Price Target

OSTX Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OS Therapies Inc. is demonstrating strong regulatory momentum for its lead candidate, OST-HER2, now having received an upgraded meeting status from the FDA, indicating alignment toward a potential Accelerated Approval pathway. The company benefits from multiple regulatory designations that may facilitate expedited review, alongside promising clinical data showing statistically significant event-free survival and overall survival in pulmonary metastatic osteosarcoma. Furthermore, the potential for a Priority Review Voucher, valued at approximately $205 million, adds strategic financial value, enhancing the outlook for OS Therapies in the biopharmaceutical market.

Bears say

OS Therapies Inc exhibited a significant increase in operating losses, reporting a loss of $28.75 million in 2025 compared to $8.82 million in 2024, which highlights a troubling trend in cost management as the company expands its development and regulatory efforts. The substantial rise in expenses may strain the company's financial resources and raise concerns about its sustainability in an already challenging clinical stage environment. Furthermore, this elevated cost base could hinder OS Therapies' ability to fund its promising pipeline of treatments for osteosarcoma and other solid tumors, potentially impacting investor confidence and future funding prospects.

OSTX has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OS Therapies Inc (OSTX) Forecast

Analysts have given OSTX a Strong Buy based on their latest research and market trends.

According to 2 analysts, OSTX has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OS Therapies Inc (OSTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.